Dyne Therapeutics Inc’s filing revealed that its Chief Scientific Officer Beskrovnaya Oxana unloaded Company’s shares for reported $36242.0 on Feb 18 ’25. In the deal valued at $13.95 per share,2,598 shares were sold. As a result of this transaction, Beskrovnaya Oxana now holds 199,087 shares worth roughly $2.45 million.
Then, Scalzo Richard William sold 2,488 shares, generating $34,708 in total proceeds. Upon selling the shares at $13.95, the SVP, Head of Finance & Admin. now owns 124,590 shares.
Before that, Scalzo Richard William bought 2,488 shares. Dyne Therapeutics Inc shares valued at $34,608 were divested by the Officer at a price of $13.91 per share.
Robert W. Baird initiated its Dyne Therapeutics Inc [DYN] rating to an Outperform in a research note published on December 13, 2024; the price target was $46. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late November with a ‘”an Outperform”‘ rating. JP Morgan also remained covering DYN and has decreased its forecast on October 24, 2024 with a “Neutral” recommendation from previously “an Overweight” rating. Chardan Capital Markets maintained its rating on May 21, 2024. It rated DYN as “a Buy”.
Price Performance Review of DYN
On Monday, Dyne Therapeutics Inc [NASDAQ:DYN] saw its stock fall -9.48% to $12.32. Over the last five days, the stock has lost -9.35%. Dyne Therapeutics Inc shares have fallen nearly -47.71% since the year began. Nevertheless, the stocks have fallen -50.68% over the past one year. While a 52-week high of $47.45 was reached on 01/02/25, a 52-week low of $12.87 was recorded on 03/03/25. SMA at 50 days reached $17.23, while 200 days put it at $30.44.
Levels Of Support And Resistance For DYN Stock
The 24-hour chart illustrates a support level at 11.83, which if violated will result in even more drops to 11.35. On the upside, there is a resistance level at 13.25. A further resistance level may holdings at 14.19. The Relative Strength Index (RSI) on the 14-day chart is 31.83, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.61, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.23%. Stochastics %K at 11.31% indicates the stock is a buying.
The most recent change occurred on April 30, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $40 price target.
